Anteris (ASX:AVR) share price drops 7% despite positive announcement

The Anteris (ASX: AVR) share price has plunged 7.6% today despite a positive announcement from the medical company.
The post Anteris (ASX:AVR) share price drops 7% despite positive announcement appeared first on The Motley Fool Australia. –

falling healthcare asx share price Mesoblast capital raising

The Anteris Technologies Ltd (ASX: AVR) share price is plunging today despite the company declaring “outstanding” results from one of its medical products.

At the time of writing, shares in the medical technology company are trading at $11.9, down 7.67%. By comparison S&P/ASX All Ordinaries Index (ASX: XAO) is down 0.14%.

Anteris, formerly known as Admedus Ltd, focuses on designing and manufacturing heart valves. Its next-generation technology re-engineers xenograft tissue into pure collagen scaffold, helping surgeons replace valves for patients during surgery.

What did Anteris announce today?

The Anteris share price is not responding well to today’s positive news. In a statement to the ASX, Anteris reported its ADAPT treated tissue has “superior anti-calcification attributes compared with tissues used in competitor valves”.

ADAPT is an anti-calcification treatment for human heart valves. Up to 20,000 people worldwide live with ADAPT technology inside their bodies.

According to Anteris, a review conducted by an independent biostatistician showed ADAPT-treated valve tissue had 38% calcium concentration compared to US company Medtronic‘s pig aortic valve. It also had 26% less calcium concentrate than Medtronic’s cow aortic valve tissue. Porcine valve is used most commonly, but bovine valve is also used in valve replacement surgery.

According to the Mayo Clinic, aortic valve calcification is an early indicator of heart disease.

Words from the CEO

Commenting on the findings, Anteris CEO Wayne Paterson said:

These findings clearly demonstrated the superior performance of the ADAPT tissue engineered process as an anti-calcification technology against some of the top competitors in the marketplace.

It further supports previous human studies and clinical experience demonstrating ADAPT has a clinically relevant profile in terms of resisting calcification.

Anteris share price snapshot

The Anteris share price has shot up 168.53% over the last 12 months and surged an incredible 210.05% this year alone. 

On 9 March, the company was hit with a price query from the ASX to explain why its share price increased 79.97% over the space of just 10 days with no significant market announcements made during that time.

Anteris has a market capitalisation of $84.7 million.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Anteris (ASX:AVR) share price drops 7% despite positive announcement appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!